BIOCON, Inc., Pfizer Inc. In Potential $350 Million Insulin Licensing Deal
Creating an alliance to deliver insulin treatments worldwide, Biocon and Pfizer have entered into a global commercialisation agreement. Pfizer will make an upfront payment of USD 200 million in a licensing deal for Biocon’s biosimilar insulin portfolio for diabetes treatment. As per the agreement, Biocon will also be eligible to get additional payments of up to USD 150 million. These payments will be linked to sales of Biocon’s insulin biosimilars. In an interview with CNBC-TV18, Vikas Dandekar of pharmasianews.com gave his perspective on the deal. Excerpts from Reporter's Diary on CNBC-TV18 Watch the full show » Q: What do you make of this arrangement? First of all tell is what is the potential the market size as far as this insulin is concerned and what does this mean both for Biocon and Pfizer? A: A number of biosimilars are scheduled to be launched in the European market. A number of trials are going on, on insulin and this is a big potenti...